医学
伊马替尼
重症监护室
2019年冠状病毒病(COVID-19)
机械通风
内皮功能障碍
酪氨酸激酶抑制剂
酪氨酸激酶
炎症
2019-20冠状病毒爆发
内科学
作者
Erik Duijvelaar,Job R Schippers,Patrick J Smeele,Michiel Alexander de Raaf,Arthur L E M Vanhove,Siebe G Blok,Jos W R Twisk,Anton Vonk Noordegraaf,Frances S de Man,Harm Jan Bogaard,Jurjan Aman
标识
DOI:10.1016/s2213-2600(22)00052-2
摘要
Hypoxaemia in COVID-19 is primarily caused by disruption of the alveolocapillary barrier on inflammation and dysfunction of the endothelium.1 To date, antiviral or immune-modulatory treatment options have been thoroughly studied, yet there is no approved therapy targeting endothelial dysfunction. Imatinib is a tyrosine kinase inhibitor that attenuates vascular leakage under inflammatory conditions.2 In the CounterCOVID study, patients admitted to hospital with COVID-19 treated with imatinib had a shorter duration of invasive ventilation and shorter stay at the intensive care unit (ICU).
科研通智能强力驱动
Strongly Powered by AbleSci AI